前不久,美国布法罗大学(UB)医学与生物医学科学学院开展的一项动物研究结果表明,一种口服的生物药物可成功治疗肠道中的慢性癌前期炎症。这项研究以封面文章的形式发表在近期的《癌症研究》杂志。该杂志的编辑称这项研究结果“不同寻常”。结肠或息肉中的炎性细胞在50岁以上人群中是很常见的。一般60岁的人当中,估计有25%患息肉的机会。大多数息肉是良性的,但有些会发展成为结肠癌。因此,息肉的治疗标准是去除它们。 Not long ago, an animal study conducted by UB’s School of Medicine and Biomedical Sciences showed that an oral biopharmaceutical can successfully treat chronic precancerous inflammation in the intestine. The study was published in a cover story in a recent issue of Cancer Research. The magazine’s editor called the study “unusual”. Inflammatory cells in the colon or polyp are common in people over 50 years of age. In the general 60-year-olds, an estimated 25% chance of getting polyps. Most polyps are benign, but some develop colon cancer. Therefore, polyps treatment criteria is to remove them.